Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • Background: Oral anticoagulant use is common among patients undergoing pacemaker or defibrillator surgery. BRUISE CONTROL (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial; NCT00800137) demonstrated that perioperative warfarin continuation reduced clinically significant hematomas (CSH) by 80% compared with heparin bridging (3.5% versus 16%). BRUISE-CONTROL-2 (NCT01675076) observed a similarly low risk of CSH when comparing continued versus interrupted direct oral anticoagulant (2.1% in both groups). Using patient level data from both trials, the current study aims to: (1) evaluate the effect of concomitant antiplatelet therapy on CSH, and (2) understand the relative risk of CSH in patients treated with direct oral anticoagulant versus continued warfarin. Methods: We analyzed 1343 patients included in BRUISE-CONTROL-1 and BRUISE-CONTROL-2. The primary outcome for both trials was CSH. There were 408 patients identified as having continued either a single or dual antiplatelet agent at the time of device surgery. Results: Antiplatelet use (versus nonuse) was associated with CSH in 9.8% versus 4.3% of patients ( P <0.001), and remained a strong independent predictor after multivariable adjustment (odds ratio, 1.965; 95% CI, 1.202–3.213; P =0.0071). In multivariable analysis, adjusting for antiplatelet use, there was no significant difference in CSH observed between direct oral anticoagulant use compared with continued warfarin (odds ratio, 0.858; 95% CI, 0.375–1.963; P =0.717). Conclusions: Concomitant antiplatelet therapy doubled the risk of CSH during device surgery. No difference in CSH was found between direct oral anticoagulant versus continued warfarin. In anticoagulated patients undergoing elective or semi-urgent device surgery, the patient specific benefit/risk of holding an antiplatelet should be carefully considered. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifiers: NCT00800137, NCT01675076.


  • Essebag, Vidal
  • Healey, Jeffrey Sean
  • Joza, Jacqueline
  • Nery, Pablo B
  • Kalfon, Eli
  • Leiria, Tiago LL
  • Verma, Atul
  • Ayala-Paredes, Felix
  • Coutu, Benoit
  • Sumner, Glen L
  • Becker, Giuliano
  • Philippon, François
  • Eikelboom, John
  • Sandhu, Roopinder K
  • Sapp, John
  • Leather, Richard
  • Yung, Derek
  • Thibault, Bernard
  • Simpson, Christopher S
  • Ahmad, Kamran
  • Toal, Satish
  • Sturmer, Marcio
  • Kavanagh, Katherine
  • Crystal, Eugene
  • Wells, George A
  • Krahn, Andrew D
  • Birnie, David H

publication date

  • October 2019

has subject area